OPTI Optibiotix Health Plc

TIDMOPTI

OptiBiotix Health PLC

04 May 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

4 May 2023

Investor update

OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, cardiovascular disease, diabetes and skincare, announces that Stephen O'Hara, CEO of OptiBiotix will provide a live presentation to investors via the Investor Meet Company platform on Wednesday, 24 May 2023 at 2pm BST. Stephen will use this opportunity to address some of the main questions asked by investors on OptiBiotix's first and second generation products, future prospects, sales and profitability and provide a more detailed overview on its SweetBiotix and Microbiome Modulator products.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet OptiBiotix.

To register for the presentation, please use this link: https://www.investormeetcompany.com/optibiotix-health-plc/register-investor

Investors who already follow OptiBiotix on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

 
OptiBiotix Health plc                           www.optibiotix.com 
Neil Davidson, Chairman                 Contact via Walbrook below 
Stephen O'Hara, Chief Executive 
 
Peterhouse Capital Limited (Broker)             Tel: 020 7220 9797 
Duncan Vasey / Lucy Williams 
 
Walbrook PR Ltd                                 Mob: 07876 741 001 
Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRANKNBQPBKDKPK

(END) Dow Jones Newswires

May 04, 2023 02:00 ET (06:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Ago 2023 a Set 2023

Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Set 2022 a Set 2023